Management tracks: CASI promotes Zhang to president; plus Five Prime, Black Diamond, Oyster Point, Enyo, X4, Nimbus and Canbridge

By Jonathan Block, Associate Editor and Hongjiang Li, Staff Writer | Sep 19, 2019 | 11:32 PM GMT

Cancer and generics company CASI Pharmaceuticals Inc. (NASDAQ:CASI) promoted Larry Zhang to president. He was president of the cancer and generics company's Chinese subsidiary CASI Pharmaceuticals (Beijing) Co. Ltd. Prior to joining CASI, Zhang was VP and head

Read the full 382 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE